XML 52 R46.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Significant Agreements - Additional Information (Details) $ in Millions |  | 1 Months Ended |  |  |
--- | --- | --- | --- | --- | ---
Jul. 31, 2020 USD ($) | Oct. 31, 2023 USD ($) | Apr. 30, 2023 GBP (£) | Aug. 31, 2022 USD ($) | Jul. 31, 2022 | Jan. 31, 2022 GBP (£) | Jun. 30, 2020 USD ($) | Sep. 30, 2018 USD ($) shares | Jun. 30, 2024 USD ($) shares | Jun. 30, 2024 GBP (£) shares | Dec. 31, 2023 shares | Aug. 31, 2023 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock, shares issued | shares |  |  |  |  |  |  |  |  | 0 | 0 | 0 |
License Agreement | Novartis International Pharmaceuticals Limited |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  | $ 2.5 |  |  |  |
License Agreement | Novartis International Pharmaceuticals Limited | Series B Redeemable Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock, shares issued | shares |  |  |  |  |  |  |  | 263,615 |  |  |  |
License Agreement | Cancer Research Technology and the University of Manchester |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Payment of one-time option exercise fee | £ |  |  |  |  |  | £ 250,000 |  |  |  |  |  |
Payments for achievement of specific development and regulatory approval events | £ |  |  |  |  |  | £ 19,500,000 |  |  |  |  |  |
Milestone payments relating to first and second tumor histologies | £ |  |  | £ 750,000 |  |  |  |  |  |  |  |  |
License Agreement | Amgen Clinical Trial Collaboration and Supply Agreement |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Pay for external third-party cost percentage |  |  |  |  | 50.00% |  |  |  |  |  |  |
Maximum |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Early clinical development milestone payment potential to receive |  | $ 17.0 |  |  |  |  |  |  |  |  |  |
Maximum | License Agreement | Novartis International Pharmaceuticals Limited |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Certain clinical and regulatory development milestones, agreed to make a payment |  |  |  |  |  |  |  | $ 9.0 |  |  |  |
Certain commercial sales milestones, agreed to make a payment |  |  |  |  |  |  |  | $ 20.0 |  |  |  |
Maximum | License Agreement | Cancer Research Technology and the University of Manchester |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Additional payments for achievement of specific development and regulatory approval events | £ |  |  |  |  |  |  |  |  |  | £ 18,750,000 |  |
Milestone payments of phase two relating to first and second tumor histologies | £ |  |  |  |  |  |  |  |  |  | 1,500,000 |  |
Milestone payments of phase two relating to first and second tumor histologies | £ |  |  |  |  |  |  |  |  |  | £ 2.25 |  |
GSK Collaboration Agreement | GSK |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Development and regulatory milestone payment eligible to receive |  |  |  |  |  |  |  |  | $ 13.0 |  |  |
GSK Collaboration Agreement | GSK | License Agreement |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ 100.0 |  |  |  |  |  |  |  |  |  |  |
Number of days of notice period for terminating agreement |  |  |  |  |  |  | 90 days |  |  |  |  |
Pol Theta Program |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment received for achievement of initial preclinical development milestone |  |  |  | $ 3.0 |  |  |  |  |  |  |  |
Milestone payment received clinical evaluation |  |  |  |  |  |  |  |  |  |  |  | $ 7.0
Additional payment of development milestone to achieve |  |  |  |  |  |  |  |  | 10.0 |  |  |
Pol Theta Program | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Development and regulatory milestone payment eligible to receive |  |  |  |  |  |  | $ 485.0 |  |  |  |  |
Commercial milestone payment eligible to receive |  |  |  |  |  |  | $ 475.0 |  |  |  |  |
Development milestone payment eligible to receive |  |  |  |  |  |  |  |  | $ 465.0 |  |  |
WRN Program |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Development costs sharing percentage |  |  |  |  |  |  | 20.00% |  |  |  |  |
Milestone payment received for achievement of initial preclinical development milestone |  | 3.0 |  |  |  |  |  |  |  |  |  |
Milestone payment received clinical evaluation |  | 3.0 |  |  |  |  |  |  |  |  |  |
Percentage of profit share |  |  |  |  |  |  | 50.00% |  |  |  |  |
WRN Program | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Commercial milestone payment eligible to receive |  |  |  |  |  |  | $ 475.0 |  |  |  |  |
Preclinical development milestone payment potential to receive |  | 7.0 |  |  |  |  |  |  |  |  |  |
Development milestone payment eligible to receive |  | $ 465.0 |  |  |  |  | $ 485.0 |  |  |  |  |
WRN Program | GSK |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Development costs sharing percentage |  |  |  |  |  |  | 80.00% |  |  |  |  |

X
- Definition Additional payment of development milestone to achieve. + References No definition available. + Details
Name: | idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional payments for achievement of specific development and regulatory approval events. + References No definition available. + Details
Name: | idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Certain commercial sales milestones payment to be paid. + References No definition available. + Details
Name: | idya_CertainCommercialSalesMilestonesPaymentToBePaid
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commercial milestone payment to be received. + References No definition available. + Details
Name: | idya_CommercialMilestonePaymentToBeReceived
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development and regulatory milestone payment to be paid. + References No definition available. + Details
Name: | idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development and regulatory milestone payment to be received. + References No definition available. + Details
Name: | idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development costs sharing percentage. + References No definition available. + Details
Name: | idya_DevelopmentCostsSharingPercentage
Namespace Prefix: | idya_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Development milestone payment to be received. + References No definition available. + Details
Name: | idya_DevelopmentMilestonePaymentToBeReceived
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development milestone payments of phase three relating to first and second tumor histologies. + References No definition available. + Details
Name: | idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development milestone payments of phase two relating to first and second tumor histologies. + References No definition available. + Details
Name: | idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Early clinical development milestone payment potential to receive. + References No definition available. + Details
Name: | idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payment received clinical evaluation + References No definition available. + Details
Name: | idya_MilestonePaymentReceivedClinicalEvaluation
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payment received for achievement of initial preclinical development milestone. + References No definition available. + Details
Name: | idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments relating to first and second tumor histologies. + References No definition available. + Details
Name: | idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of days of notice period for terminating collaboration agreement. + References No definition available. + Details
Name: | idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement
Namespace Prefix: | idya_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pay for external third-party cost percentage. + References No definition available. + Details
Name: | idya_PayForExternalThirdPartyCostPercentage
Namespace Prefix: | idya_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment of one-time option exercise fee. + References No definition available. + Details
Name: | idya_PaymentOfOneTimeOptionExerciseFee
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments for achievement of specific development and regulatory approval events. + References No definition available. + Details
Name: | idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of profit share. + References No definition available. + Details
Name: | idya_PercentageOfProfitShare
Namespace Prefix: | idya_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Preclinical development milestone payment potential to receive. + References No definition available. + Details
Name: | idya_PreclinicalDevelopmentMilestonePaymentPotentialToReceive
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Upfront payment. + References No definition available. + Details
Name: | idya_UpfrontPayment
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details
Name: | us-gaap_PreferredStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=idya_NovartisInternationalPharmaceuticalsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=idya_SeriesBRedeemableConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_GlaxoSmithKlineCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=idya_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |